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A B S T R A C T
Background
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral oedema, the accumulation of fluid within
the brain, is believed to be an important contributor to the secondary brain damage that occurs following injury. The release of kinins
is thought to be an important factor in the development of cerebral vasogenic oedema and the use of bradykinin beta-2 receptor
antagonists, which prevent the release of these kinins, has been proposed as a potential therapeutic intervention.
Objectives
The objective was to assess the safety and effectiveness of bradykinin beta-2 receptor antagonists for TBI.
Search methods
We searched the Cochrane Injuries Group Specialised Register, Cochrane Central Register of Controlled Trials (The Cochrane Library
2010 Issue 2), MEDLINE (Ovid SP), EMBASE (Ovid SP), ISIWeb of Science: Science Citation Index Expanded (SCI-EXPANDED),
ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S), Zetoc: British Library’s table of contents of journal
articles and conference proceedings, PubMed, and Current Controlled Trials covering all available years up to 20th May 2010. We also
searched the Internet and checked the reference lists of relevant papers and other reviews to identify any further studies.
Selection criteria
Randomised controlled trials of beta-2 receptor antagonists versus placebo for TBI.
Data collection and analysis
Two authors independently screened search results and assessed the full texts of potentially relevant studies for inclusion. Data were
extracted and the risks of bias assessed. Relative risks (RR) and 95% confidence intervals (CIs) were calculated and data were pooled
using a fixed-effect model.
Main results
Four studies involving 406 participants were included. All four studies reported the effects of beta-2 receptor antagonists on mortality.
The pooled RR for mortality was 0.84 (95% CI 0.55 to 1.29). Two studies measured disability and the RR of death or severe disability
with beta-2 receptor antagonists was 0.81 (95% CI 0.59 to 1.09). One trial reported data on adverse events, the RR of at least one
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serious adverse event was 1.37 (95% CI 0.76 to 2.46) and the RR of local skin reactions was 13.79 (95% CI 0.85 to 224.81). Two
studies measured the effect on intracranial pressure (ICP), only in one study did this finding reach statistical significance. There was
no evidence for the presence of heterogeneity.
Authors’ conclusions
There is no reliable evidence that bradykinin beta-2 receptor antagonists are safe or effective for use in TBI patients, and they should
not be used outside the context of well conducted trials. Further adequately powered and well conducted randomised controlled trials
are required.
P L A I N L A N G U A G E S U M M A R Y
Bradykinin beta-2 receptor antagonists for traumatic brain injury
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Not all damage to the brain occurs at the moment
of injury. The injury sustained at the moment of impact (primary brain injury) initiates a sequence of mechanisms which cause further
brain damage (secondary brain injury).
One consequence of the mechanisms triggered by primary injury is the accumulation of fluid within the brain. This condition is known
as cerebral oedema and leads to raised intracranial pressure (pressure within the skull), which contributes to secondary brain injury.
The use of a group of drugs known as bradykinin beta-2 receptor antagonists is being investigated as a potential treatment for TBI.
It is proposed that they can inhibit the mechanism which causes cerebral oedema and therefore prevent the elevation of intracranial
pressure with subsequent brain damage.
The authors of this review searched for all randomised controlled trials investigating the effects of bradykinin beta-2 receptor antagonists
in traumatically brain injured patients. The authors found four trials involving 406 patients. Whilst the overall effect estimates suggest
that bradykinin beta-2 receptor antagonists may reduce mortality and disability, they also suggest that they may increase the number
of serious adverse events. However, all of these results are consistent with the play of chance. The findings indicate that there is no
evidence to support the use of bradykinin beta-2 receptor antagonists for TBI.
Bradykinin beta-2 receptor antagonists are not presently registered for use in patients. Because the safety and effectiveness of bradykinin
beta-2 receptor antagonists have not been reliably ascertained, they should not be used outside the context of well conducted trials.
B A C K G R O U N D
Description of the condition
Traumatic brain injury (TBI), defined as a blow or jolt to the head
or penetrating head injury that disrupts the function of the brain
(CDC 2006), is a leading cause of death and disability worldwide.
The majority of TBI occurs in the 15 to 45 years age group, with
the highest rate amongst males (Bruns 2003; Tagliaferri 2006).
Road traffic crashes (RTCs) are the leading cause of TBI account-
ing for 40% to 50% of serious injuries, followed by falls and vio-
lence (WHO 2006). A review of European epidemiological data
by Tagliaferri 2006 et al estimated a TBI (hospitalised and fatal)
incidence of 235 per 100,000 per year and a case fatality rate of
11 per 100. Each year in the USA, a total of 1.4 million people
suffer a TBI, of whom an estimated 50,000 die and 235,000 are
hospitalised (CDC 2006). Almost half of all TBI patients suffer
long-term disability (Thornhill 2000; Whitnall 2006). This cou-
pled with the fact that most TBI occurs in young adults further
exacerbates themedical, social and financial burden. Furthermore,
this burden is expected to grow, particularly in low and middle
income countries, largely due to the predicted increase in RTCs
and the associated TBIs.
There are two distinct phases of injury associated with TBI. Pri-
mary injury describes the irreversible, direct injury sustained at the
moment of impact. Pathophysiological studies indicate that this
primary injury initiates a sequence of mechanisms which cause
further brain damage, known as secondary brain injury. The im-
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pact of secondary injury has been demonstrated by research in
which it was found that approximately 40% of TBI patients who
were able to speak or follow commands shortly after the event later
died from their injury (Reilly 1975).
How the intervention might work
The focus in minimising primary brain injury is placed on injury
prevention interventions, whilst secondary brain injury requires
effective therapeutic interventions to interrupt the mechanisms
that can lead to further neural damage.
Secondary brain damage is caused by physiological assaults that
result from a cascade of mechanisms which are initiated immedi-
ately after the time of the primary injury. Cerebral oedema is one
of the physiological assaults contributing to secondary brain in-
jury. There are two types of cerebral oedema, vasogenic and cyto-
toxic. Vasogenic oedema involves the accumulation of fluid within
the brain that results from the opening of the blood-brain barrier
(BBB), while cytotoxic oedema is due to sustained intracellular
water collection (Unterberg 1991; Vincent 2005).
Vasogenic cerebral oedema is thought to be, in part, caused by a
sequence of events that begins with the release of kinins, prod-
ucts of the kinin-kallikrein system (Francel 1992; Mayhan 1996;
Unterberg 1991). These kinins stimulate a number of neurochem-
ical disturbances which are thought to initiate and potentiate cere-
bral oedema (Marmarou 2005). In particular, bradykinin (BK) is
believed to contribute to the breakdown of the endothelial junc-
tions that comprise the BBB, which enables the movement of sub-
stances into the brain and leads to an accumulation of fluid, that
is causing vasogenic cerebral oedema (Unterberg 1991; Unterberg
2004). This is thought to further increase intracranial pressure,
which can lead to cerebral ischaemia and additional structural neu-
ral damage (Vincent 2005).
In consideration of the role of kinins in vasogenic oedema and
their contribution to secondary brain injury, the use of beta-2 re-
ceptor antagonists has been proposed (Francel 1992; Marmarou
1999). These agents act to block the activity of the kinin-kallikrein
system, thus preventing the production of kinins and their impact
on the BBB. In this way it is hypothesised that the administration
of bradykinin beta-2 antagonists can prevent elevation of intracra-
nial pressure. There are promising results for the effects of beta-2
receptor antagonists on neurological function and brain oedema
from studies in animal models of TBI (Ivashkova 2006; Kaplanski
2002; Stover 2000).
Why it is important to do this review
Beta-2 receptor antagonists are not registered for use in traumati-
cally brain injured patients. The evidence for the effectiveness and
safety of the use of bradykinin beta-2 antagonists in TBI has yet
to be ascertained. Hence we conducted a systematic review of ran-
domised controlled trials.
O B J E C T I V E S
To assess the evidence on the effects of bradykinin beta-2 receptor
antagonists for the treatment of acute traumatic brain injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Patients of any agewith acute traumatic brain injury of any severity.
Types of interventions
Bradykinin beta-2 receptor antagonists versus placebo.
For studies in which different doses of the intervention drug were
compared with placebo, the intervention groups were combined
and compared with the control group.
Types of outcome measures
Primary outcomes
• Mortality
• Disability as measured on the Glasgow Outcome Score
(GOS)
Secondary outcomes
• Intracranial pressure (ICP)
• S100B levels
• Side effects, including local skin reactions
Search methods for identification of studies
Searcheswere not restricted by date, language or publication status.
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Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group’s Specialised Register (searched 20
May 2010)
• Cochrane Central Register of Controlled Trials (The
Cochrane Library 2010 Issue 2)
• MEDLINE (Ovid SP) 1950 to May (week 1) 2010
• EMBASE (Ovid SP) 1980 to (week 19) May 2010
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) 1970 to May 2010
• ISI Web of Science: Conference Proceedings Citation
Index- Science (CPCI-S) 1990 to May 2010
• Zetoc: British Library’s table of contents of journal articles
and conference proceedings (http://zetoc.mimas.ac.uk/)
(searched 20 May 2010)
• PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 20
May 2010 (limit: added in the last 90 days)
• LILACS (to May 2010)
• Current Controlled Trials (to May 2010),
The full search strategies are presented in Appendix 1.
Searching other resources
We searched the reference lists of the eligible studies and any review
articles for further potentially eligible articles. We searched the
Internet using the Google (www.google.com) search engine, with
selected terms from the above strategy, for any further unpublished
or grey literature.
Data collection and analysis
Selection of studies
Two authors independently examined titles, abstracts, and key-
words of citations from electronic databases for eligibility of stud-
ies. We obtained the full text of all potentially relevant records
and two authors independently assessed whether eachmet the pre-
defined inclusion criteria. We resolved any disagreements by dis-
cussion.
Data extraction and management
Two authors extracted data from each eligible study using a stan-
dard form that was developed specifically for this review. We ex-
tracted data on the following:
• study design;
• participant characteristics;
• intervention characteristics;
• outcome measures;
• statistical analysis.
Assessment of risk of bias in included studies
This was assessed using The Cochrane Collaboration’s tool for
assessing risk of bias presented in Higgins 2008.
The following domains were assessed for each study:
• sequence generation,
• allocation concealment,
• blinding,
• incomplete outcome data,
• other potential sources of bias.
We completed a risk of bias table for each study, incorporating a
description of the study’s performance against each of the above
domains and our overall judgment of the risk of bias for each entry,
as follows:
• ’Yes’ indicates low risk of bias,
• ’Unclear’ indicates unclear or unknown risk of bias,
• ’No’ indicates high risk of bias.
Measures of treatment effect
We calculated relative risks (RR) and 95% confidence intervals
(CI) for mortality for each trial. RR and 95% CIs were also calcu-
lated for GOS data, whichwe dichotomised into favourable (mod-
erate disability, good recovery; GOS 4 and 5) and unfavourable
(death, vegetative state, severe disability; GOS 1 to 3) outcomes.
Dealing with missing data
We contacted the original investigators to obtain missing data.
Assessment of heterogeneity
We examined trial characteristics in terms of participants, inter-
ventions and outcomes for evidence of clinical heterogeneity. Sta-
tistical heterogeneity was examined by both the I2 and Chi2 statis-
tics. The I2 statistic describes the percentage of total variation
across studies due to heterogeneity rather than chance. A value of
0% indicates no observed heterogeneity, and larger values show
increasing heterogeneity; substantial heterogeneity is considered
to exist with I2 > 50% (Higgins 2008). For the Chi2 statistic, a
P value of < 0.10 was used to indicate the presence of statistically
significant heterogeneity.
Possible sources of heterogeneity were assessed by subgroup and
sensitivity analyses, as described below.
Assessment of reporting biases
We planned to investigate the presence of reporting (publication)
bias using funnel plots, however there were too few included stud-
ies to enable meaningful analysis.
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Data synthesis
We judged that the trials were sufficiently homogenous, both clini-
cally and statistically, and pooled data using the fixed-effectmodel.
Subgroup analysis and investigation of heterogeneity
Weplanned to conduct a subgroup analysis according to the sever-
ity of TBI (mild and moderate; GCS 9 to 15) versus severe (GCS
3 to 8) assuming that there was at least one study in each category.
However there were insufficient data for such an analysis.
Sensitivity analysis
We planned to conduct a sensitivity analysis according to allo-
cation concealment (adequate versus inadequate) assuming that
there was at least one study in each category. However there were
insufficient data for such an analysis.
R E S U L T S
Description of studies
See: Characteristics of included studies.
Results of the search
The combined search strategy identified 254 citations, of which 23
were judged to be potentially eligible based on title or abstract, or
both, and the full texts were obtained. After a full text review, four
completed studies (BRAIN 2009; Marmarou 1999; Marmarou
2005;Narotam1998)were judged to be eligible andwere included
in this review.
Included studies
Two studies were conducted in the USA, one in South Africa and
one was an international, multi-centre trial. Sample sizes were n
= 228, n = 133, n = 25 and n = 20 for BRAIN 2009, Marmarou
1999, Marmarou 2005 and Narotam 1998, respectively.
The BRAIN 2009 trial recruited patients aged 16 to 65 years with
aGCS≤ 12 and a computerised tomography (CT) scan indicating
the presence of an intracranial abnormality consistent with trauma
who presented within eight hours of injury. Marmarou 1999 and
Marmarou 2005 involved patients aged 16 to 70 years with a severe
TBI (GCS 3 to 8), while Narotam 1998 recruited patients aged
12 years and over with moderate TBI (GCS 9 to 12).
Patients in the BRAIN 2009 trial were allocated to one of four
groups: low dose (10 mg loading dose + 5 mg/day), medium dose
(20 mg loading dose + 10 mg/day), high dose (30 loading dose +
15 mg/day) Anatibant®, or placebo.
Marmarou 1999 compared a group receiving continuous intra-
venous infusion of 3 µg/kg/min of Bradycor™ with a control
group receiving placebo (reconstituted with lactated Ringer’s so-
lution).
Patients were randomised to three treatment arms in Marmarou
2005: one group received a single dose of 3.75 mg Anatibant®,
the second group received a single dose of 22.5 mg Anatibant®,
and the final group was the control and received placebo.
The intervention group in Narotam 1998 received 3 µg/kg/min
of Bradycor™ (CP-0127) over a seven-day period and the control
group received placebo (lactated Ringer’s solution).
All four studies measured mortality. In addition, BRAIN 2009
measured serious adverse events and in-hospital morbidity (GCS,
Disability Rating Scale,OxfordHandicap Scale);Marmarou 1999
and Marmarou 2005 also measured ICP and long-term disability
according to the GOS.
Further details are presented in the ’Characteristics of included
studies’ table.
Risk of bias in included studies
For further details regarding the performance of the studies against
each domain, please see the ’Risk of bias’ tables and Figure 1 and
Figure 2.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality item
presented as percentages across all included studies. Please note that four trials are included in this review.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
Adequate sequence generation
Acomputer-generated randomisation list was used in all four trials,
thus the risk of bias for this item was judged to be low.
Allocation concealment
Allocation concealment was judged to be adequate in BRAIN
2009 and Marmarou 1999. There was insufficient information
presented to determine the adequacy of allocation concealment in
Marmarou 2005 and Narotam 1998.
The risk of bias for this item was judged as unclear for Marmarou
2005 and Narotam 1998, and low for BRAIN 2009 and
Marmarou 1999.
Blinding
All three trials reported that the treating clinicians were blind to
allocation status, although in Narotam 1998 two physicians were
not blinded for safety reasons.
For Marmarou 1999 andMarmarou 2005 it is unclear if outcome
assessors were blind to allocation status. In Narotam 1998 they are
reported as being blind to allocation. In BRAIN 2009 all study
personnel and participants were blind to allocation status.
The risk of bias for this item was judged as unclear for Marmarou
1999 and Marmarou 2005, and low for BRAIN 2009 and
Narotam 1998.
Incomplete outcome data
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Reasons for the attrition or exclusion of participants were not
reported in Marmarou 1999 or Marmarou 2005. In Narotam
1998 there were no withdrawals, drop-outs, attrition differences
between groups or losses to follow up. In BRAIN 2009 there was
a small amount of missing data for certain outcomes, although
reasons for this were unlikely to be related to true outcomes and
analyses were performed on an intention-to-treat basis.
The risk of bias for this item was judged as unclear for Marmarou
1999 and Marmarou 2005, and low for BRAIN 2009 and
Narotam 1998.
Selective reporting
We were able to access the protocol for one (BRAIN 2009) of the
included trials.
In themethods ofMarmarou 2005 it was stated that ICP outcome
data were collected, however such data were not presented in the
results.
The risk of bias for this item was judged as low for BRAIN 2009,
unclear for Marmarou 1999 and Narotam 1998, and high for
Marmarou 2005.
Other potential sources of bias
In Marmarou 2005 dilution errors resulted in an incorrect dosage
of the active drug being administered to some intervention pa-
tients. Additionally there were between-group differences in terms
of TBI severity of the participants.
The source of funding of Marmarou 2005 was not reported.
BRAIN2009,Marmarou 1999 andNarotam1998were all funded
by pharmaceutical companies involved in the development of the
intervention drug.
The risk of bias for this item was judged as low for BRAIN 2009,
Marmarou 1999 and Narotam 1998; and high for Marmarou
2005.
Effects of interventions
Mortality
All four included studies reported mortality data. The pooled rel-
ative risk (RR) of death at end of follow up was RR 0.84 (95%
CI 0.55 to 1.29). There was no evidence of heterogeneity (Chi2 =
3.34, df = 2, P = 0.19, I2 = 40%).
Disability
Two studies reported disability data measured on the GOS. The
pooled RR for death or severe disability (GOS 1 to 3) was 0.81
(95% CI 0.59 to 1.09). There was no evidence of heterogeneity
(Chi2 = 0.02, df = 1, P = 0.89, I2 = 0%).
Intracranial pressure (ICP)
Three studies reported collecting ICP data as outcome mea-
sures, however data were only presented in two (Marmarou 1999;
Narotam 1998). A pooled analysis was not appropriate and the
data are presented narratively below. Both studies detected a bene-
ficial effect of beta-2 antagonists on controlling ICP, although the
effect was statistically significant for just one study.
Marmarou 1999
Mean per cent time above 20 mm Hg for patients in the inter-
vention group was consistently lower than the control group for
the first five days post-injury, although the differences in the daily
means were not statistically significant.
Narotam 1998
Elevated ICP (defined as sustained elevations of > 20 mm Hg)
occurred in one of the 11 patients in the intervention group com-
pared to seven of the nine control patients (P = 0.005). The mean
peak ICP in the control group was 33.56 (± 4.47) mm Hg which
occurred at a mean of 2.78 (± 0.47) days after injury; and 20.0 (±
1.92) mmHg in the intervention group, occurring at a mean 4.16
(± 0.52) days after injury. The mean change in peak ICP from
baseline in the intervention group was 9.45 (± 2.01) which was
significantly lower than that in the control group (21.89 ± 4.69),
P = 0.0018.
S100B levels
None of the included studies reported data on S100B levels.
Adverse events
Local skin reactions
Two studies (BRAIN 2009; Marmarou 2005) collected data on
local skin reactions as a potential adverse effect of the intervention,
although only the BRAIN 2009 trial presented the figures. The
RR for local skin reaction was 13.79 (95% CI 0.85 to 224.81).
The actual outcome datawere not reported inMarmarou 2005, al-
though it was stated that “all the local injection sites reactions (ery-
thema and subcutaneous nodules), the incidence of which tended
to increase with the concentration of Anatibant, reversed sponta-
neously”.
Serious adverse events
The BRAIN 2009 trial collected data on serious adverse events.
These were defined as any untoward medical occurrence that: 1)
was fatal; 2) life threatening; 3) required or prolonged hospitalisa-
tion; 4) resulted in persistent or significant disability or incapacity;
5) was medically significant in that it may jeopardise the patient
and may require medical or surgical interventions to prevent one
of the outcomes listed above; or 6) congential anomalies.
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The number of patients with at least one serious adverse event was
higher in the intervention group. The RR for at least one serious
adverse event was 1.37 (95% CI 0.76 to 2.46).
Subgroup analysis
There were insufficient data to perform subgroup analyses.
D I S C U S S I O N
Summary of main results
There is no reliable evidence that bradykinin beta-2 receptor an-
tagonists are effective or safe for use in patients with traumatic
brain injury (TBI). Whilst the pooled effect estimates show non-
significant reductions in mortality and severe disability with beta-
2 receptor antagonists, they also indicate a non-significant increase
in serious adverse events. However, all of these findings are con-
sistent with the play of chance.
These findings are based on four RCTs involving 406TBI patients.
Quality of the evidence
Two of the included studies were judged to have adequate allo-
cation concealment, for the remaining two studies this was rated
as unclear. Blinding of outcome assessors was unclear in the two
trials that collected long-term GOS disability data.
Marmarou 1999 originally aimed to recruit 160 patients, 80
in each study arm, however the sponsor (SmithKline Beecham)
stopped recruitment at 139 patients. The reason for this action was
reported as being “because of results of animal toxicology studies
conducted during the course of the trial. These results, although
largely inconclusive after repeat studies were performed, were suf-
ficient to prompt SmithKline Beecham to terminate the trial”. Al-
though 139 patients were enrolled, data were only presented for
133 and the reason for the exclusion of six patients was not given.
For outcomes at six months, data were presented for 116 partici-
pants (58 in each group), thus a total of 17 (13%) patients were
not included in the analysis. The reasons for these exclusions were
not explicit in the trial report.
BRAIN 2009 was a well conducted trial, judged to be at low risk
of bias for all domains. The trialists originally planned to recruit
400 patients however recruitment was stopped by the sponsor at
228 participants, consequently the trial’s power to detect an effect
was reduced.
The small sample size is likely to be the reason for the uneven
distribution in the severity of TBI noted inMarmarou 2005. Based
on GCS at baseline, patients allocated to the intervention group
were more severely injured than patients in the control group.
There were also dosage errors in administration of the study drug,
which meant that the exact allocated dose was not given in some
patients.
The length of time between injury and administration of the drug
in the trials may be considered a potential weakness. The inflam-
matory process is understood to be initiated immediately after in-
jury. It therefore may be reasonable to believe that a treatment
aimed at interrupting this process needs to be administered as early
as possible to maximise any beneficial effect. The shortest eligi-
ble time period adopted in the included trials was within eight
hours of injury, used in both BRAIN 2009 and Marmarou 2005,
which still may have meant that patients were treated with beta-
2 receptor antagonists relatively late in the inflammatory process.
Future trials might consider adopting a more restrictive eligibility
criterion in terms of time since injury, in an attempt to adminis-
ter the treatment as early as possible in the inflammatory process.
However, any time period has to also be clinically feasible.
Potential biases in the review process
This systematic review addresses a focused research question and
uses pre-defined inclusion criteria and methodology to select and
appraise eligible studies.
As with all systematic reviews, the possibility of publication bias
should be considered as a potential threat to validity. However, in
light of our extensive and sensitive searching we believe that the
risk of such a bias affecting the results is minimal.
For the mortality outcome we pooled the number of deaths at the
end of the follow-up period in each trial. For Marmarou 1999
and Marmarou 2005 this was six months, for BRAIN 2009 and
Narotam 1998 it was 15 and 14 days, respectively. Pooling data
from such different lengths of follow up may be considered a
potential weakness.
There were a number of points on which we sought further clar-
ification from the trial authors. Unfortunately we did not receive
a response to our queries regarding either Marmarou 1999 or
Marmarou 2005.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Bradykinin beta-2 receptor antagonists are not licensed for use in
TBI patients.
Because the safety and effectiveness of beta-2 receptor antagonists
have yet to be reliably ascertained, these agents should not be used
outside the context of well conducted RCTs.
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Implications for research
Further adequately powered well designed RCTs are required to
determine the the safety and effectiveness of beta-2 receptor an-
tagonists in TBI patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BRAIN 2009
Methods Trial location: International, multi-centre.
Participants n = 228 TBI patients aged 16 to 65 years with a GCS of 12 or less, with a CT scan
showing an intracranial abnormality consistent with trauma and presenting within 8
hours of injury
Interventions Four groups:
• low dose (10mg loading dose + 5mg/day) Anatibant, n=58
• medium dose (20mg loading dose + 10mg/day) Anatibant, n=56
• high dose (30 loading dose + 15mg/day) Anatibant, n=57
• placebo, n=57
Data from intervention groups were combined for the review’s analyses
Outcomes Mortality.
In-hospital morbidity (assessed by GCS, DRS and HIREOS).
15-day follow up.
Notes Funded by Xytis Pharmaceuticals.
Planned sample size of 400, sponsor stopped trial after recruitment of 228 patients
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer randomisation.
Allocation concealment? Yes Central allocation.
Blinding?
All outcomes
Yes “All study personnel and participants were
to be blinded to treatment assignment for
the duration of the study”
Incomplete outcome data addressed?
All outcomes
Yes Reasons for missing outcome data unlikely
to be related to true outcome. Intention-
to-treat analysis performed
Free of selective reporting? Yes Data for all outcomes pre-specified in the
trial protocol are presented in the final re-
port
Free of other bias? Yes The study appears to be free of other
sources of bias.
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Marmarou 1999
Methods Trial location: USA.
Participants Patients aged 16 to 70 years with severe traumatic brain injury (GCS 3 to 8).
139 patients recruited, 133 patients were randomised and received allocated treatment,
reasons for exclusion of the six patients were not reported
Interventions Two groups.
Intervention: n = 66, 3ug/kg/min Bradycor - continuous iv infusion over five days.
Infusion beginning within 12 hours of injury.
Control: n = 67, placebo (reconstituted with lactated Ringer’s solution)
Outcomes Mortality.
GOS at three and six months.
ICP measurements.
Blood pressure.
Heart rate.
Therapeutic intervention.
GCS.
Neuropsychological tests.
Adverse events.
Length of follow up: first 14 days, long-term outcome assessed at three and six months
after injury
Notes Trial sponsored by SmithKline Beecham Pharmaceuticals.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A computer-generated randomisation list with sequential blocks
of four randomisation numbers assigned to each site
Allocation concealment? Yes The study drug and placebo were identical in appearance and
packaging
Blinding?
All outcomes
Unclear Study personnel were blinded to allocation status. It is unclear
whether long-term outcome assessors of disability at three and
six months were blinded to allocation status
Incomplete outcome data addressed?
All outcomes
Unclear The report states that the sponsor stopped the trial at an accrual
of 139 patients, 133 of these were randomised and received the
allocated dose, subsequent analyses are based on these 133 pa-
tients. The reason for the exclusion of the six remaining partic-
ipants is not stated
13% (n = 17) of patients were lost (or excluded) at six months
Free of selective reporting? Unclear We were unable to locate the protocol for this trial.
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Marmarou 1999 (Continued)
Free of other bias? Yes The study appears to be free of other sources of bias.
Marmarou 2005
Methods Trial location: USA.
Participants Patients aged 16 to 70 years with severe traumatic brain injury (GCS 3 to 8 or if intubated
a motor score of 2 to 5).
25 patients were randomised.
Interventions Intervention 1: n = 10 received single dose of 3.75mg Anatibant.
Intervention 2: n = 10 received single dose of 22.5mg Anatibant.
Control: n = 5 received placebo.
Administered within eight hours of injury, or 12 hours if surgery was required
Outcomes GOS at one, three and six months after injury.
Pharmacokinetic assessments.
ICP recorded for the first five days.
Therapeutic interventions.
Vital signs and body temperature.
Assessment of GCS - daily.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A computer-generated randomisation was used to allocate pa-
tients
Allocation concealment? Unclear Patients were sequentially assigned to a randomisation number
and to the matching treatment
Blinding?
All outcomes
Unclear Clinicians were blinded to allocation status. It is unclear whether
long-term outcome assessors were blind to allocation status
Incomplete outcome data addressed?
All outcomes
Unclear Twenty-five patients were randomised; one patient in the control
group died before treatment and was excluded from the trial’s
analyses (NB this death has been included in this review’s anal-
yses)
8% of patients were lost to follow up at six months.
Free of selective reporting? No We were unable to locate the protocol for this trial.
In the trial’s methods section it stated that outcome data on
intracranial pressure were collected, however these data were not
reported in the results section
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Marmarou 2005 (Continued)
Free of other bias? No Due to dilution errors the exact doses of 3.75mg and 22.5mg
were not administered in some patients. Comparison of baseline
characteristics indicated that patients randomised to interven-
tion group were more severely injured, and amongst interven-
tion groups those in 3.75mg group were more severely injured
than the 22.5mg group
Narotam 1998
Methods Trial location: Durban, South Africa.
Participants Patients aged 12 years and over with focal closed traumatic brain injury (GCS 9 to 14),
presenting within 24 and 96 hours of injury.
20 patients were randomised.
Interventions Two groups.
Intervention: n = 11 received Bradycor CP-0127 (3ug/kg/min) over a seven day period.
Control: n = 9 received placebo (lactated Ringer’s solution)
Outcomes Control of ICP, improvement in neurological function (measured by GCS), need for
surgical interventions to excise the contusion.
Monitoring of vital signs and laboratory parameters.
Maintenance of adequate CPP.
Adverse events.
14-day all-cause mortality.
Notes Trial funded by Cortech Inc - inventor and owner of CP-0127.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised according to a com-
puter-generated randomisation code
Allocation concealment? Unclear No information reported.
Blinding?
All outcomes
Yes This was an open label study. Two physicians
in the study group were aware of allocation sta-
tus for safety reasons, although actively treat-
ing physicians were blinded. Outcome assessors
were blind to allocation status
Incomplete outcome data addressed?
All outcomes
Yes No withdrawals, drop-outs, attrition between
groups or losses to follow up reported
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Narotam 1998 (Continued)
Free of selective reporting? Unclear We were unable to locate the protocol for this
trial.
Free of other bias? Yes The study appears to be free of other sources of
bias.
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D A T A A N D A N A L Y S E S
Comparison 1. Beta-2 receptor antagonist versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at end of follow-up
period
4 379 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.55, 1.29]
2 Death or severe disability (GOS
1 to 3) at end of follow-up
period
2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.59, 1.09]
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Skin reactions at injection
site
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Serious adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Beta-2 receptor antagonist versus placebo, Outcome 1 Mortality at end of
follow-up period.
Review: Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Comparison: 1 Beta-2 receptor antagonist versus placebo
Outcome: 1 Mortality at end of follow-up period
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BRAIN 2009 31/163 9/57 37.4 % 1.20 [ 0.61, 2.37 ]
Marmarou 1999 13/58 19/58 53.3 % 0.68 [ 0.37, 1.25 ]
Marmarou 2005 3/19 2/4 9.3 % 0.32 [ 0.08, 1.32 ]
Narotam 1998 0/11 0/9 Not estimable
Total (95% CI) 251 128 100.0 % 0.84 [ 0.55, 1.29 ]
Total events: 47 (Treatment), 30 (Control)
Heterogeneity: Chi2 = 3.34, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.77 (P = 0.44)
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Beta-2 receptor antagonist versus placebo, Outcome 2 Death or severe
disability (GOS 1 to 3) at end of follow-up period.
Review: Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Comparison: 1 Beta-2 receptor antagonist versus placebo
Outcome: 2 Death or severe disability (GOS 1 to 3) at end of follow-up period
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Marmarou 1999 28/58 35/58 87.6 % 0.80 [ 0.57, 1.12 ]
Marmarou 2005 12/19 3/4 12.4 % 0.84 [ 0.43, 1.63 ]
Total (95% CI) 77 62 100.0 % 0.81 [ 0.59, 1.09 ]
Total events: 40 (Treatment), 38 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.3. Comparison 1 Beta-2 receptor antagonist versus placebo, Outcome 3 Adverse events.
Review: Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Comparison: 1 Beta-2 receptor antagonist versus placebo
Outcome: 3 Adverse events
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin reactions at injection site
BRAIN 2009 19/163 0/57 13.79 [ 0.85, 224.81 ]
2 Serious adverse events
BRAIN 2009 43/163 11/57 1.37 [ 0.76, 2.46 ]
0.001 0.01 0.1 1 10 100 1000
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Injuries Group Specialised Register (searched 20 May 2010)
(beta-2 or B2 or bradycor or anatibant or icatibant or cereport or bradykinin)
Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 2)
#1 MeSH descriptor Craniocerebral Trauma explode all trees
#2 MeSH descriptor Cerebrovascular Trauma explode all trees
#3 MeSH descriptor Brain Edema explode all trees
#4 (brain or cerebral or intracranial) near3 (oedema or edema or swell*)
#5 MeSH descriptor Glasgow Coma Scale explode all trees
#6 MeSH descriptor Glasgow Outcome Scale explode all trees
#7 MeSH descriptor Unconsciousness explode all trees
#8 glasgow near3 (coma or outcome) near3 (score or scale)
#9 Unconscious* or coma* or concuss* or ’persistent vegetative state’
#10 “Rancho Los Amigos Scale”
#11 (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near3 (injur* or
trauma* or damag* or wound* or fracture* or contusion*)
#12 Diffuse near3 axonal near3 injur*
#13 (head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) near3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)
#14 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 MeSH descriptor Bradykinin explode all trees
#16 MeSH descriptor Receptor, Bradykinin B2 explode all trees
#17 bradykinin*
#18 MeSH descriptor Receptors, Adrenergic, beta-2 explode all trees
#19 (adrenergic* or antagonist*) near3 (B2 or Beta-2)
#20 Anatibant or LF16-0687 or XY2405
#21(Bradycor or CP-0127 or Icatibant or CP-0597 or Cereport)
#22 (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#14 AND #22)
MEDLINE (Ovid SP) 1950 to May (week 1) 2010
1. exp CRANIOCEREBRAL TRAUMA/
2. exp Cerebrovascular Trauma/
3. exp BRAIN EDEMA/
4. ((brain or cerebral or intracranial) adj3 (oedema or edema or swell*)).ab,ti.
5. exp GLASGOW COMA SCALE/
6. exp GLASGOWOUTCOME SCALE/
7. exp UNCONSCIOUSNESS/
8. (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti.
9. (Unconscious* or coma* or concuss* or ’persistent vegetative state’).ab,ti.
10. “Rancho Los Amigos Scale”.ab,ti.
11. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.
12. “Diffuse axonal injur*”.ab,ti.
13. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ab,ti.
14. or/1-13
15. exp Receptors, Bradykinin/
16. exp Bradykinin/
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17. bradykinin*.ab,ti.
18. exp Receptors, Adrenergic, beta-2/
19. ((adrenergic* or antagonist*) adj3 (B2 or Beta-2)).ab,ti.
20. (Anatibant or LF16-0687 or XY2405).ab,ti.
21. (Bradycor or CP-0127 or Icatibant or CP-0597 or Cereport).ab,ti.
22. or/15-21
23. 14 and 22
EMBASE (Ovid SP) 1980 to (week 19) 2010
1. exp Brain Injury/
2. exp Brain Edema/
3. exp Glasgow Coma Scale/
4. exp Glasgow Outcome Scale/
5. exp Rancho Los Amigos Scale/
6. exp Unconsciousness/
7. ((brain or cerebral or intracranial) adj3 (oedema or edema or swell*)).ab,ti.
8. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.
9. (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti.
10. Rancho Los Amigos Scale.ab,ti.
11. (Unconscious* or coma* or concuss* or ’persistent vegetative state’).ab,ti.
12. Diffuse axonal injur*.ab,ti.
13. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ab,ti.
14. or/1-13
15. exp Bradykinin Receptor/
16. exp Bradykinin/
17. bradykinin*.ab,ti.
18. exp Beta 2 Adrenergic Receptor/
19. ((adrenergic* or antagonist*) adj3 (B2 or Beta-2)).ab,ti.
20. (Anatibant or LF16-0687 or XY2405).ab,ti.
21. (Bradycor or CP-0127 or Icatibant or CP-0597 or Cereport).ab,ti.
22. or/15-21
23. 14 and 22
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to 19 May 2010 and ISI Web of Science:
Conference Proceedings Citation Index- Science (CPCI-S) 1990 to May 2010
Topic=((brain or head) SAME (injur* or trauma* or damag* or wound* or fracture* or contusion* or haematoma* or hematoma* or
haemorrhag* or hemorrhag* or bleed* or pressure)) AND Topic=(beta-2 or B2 or bradycor or anatibant or icatibant or cereport or
bradykinin) AND Topic=(random* or trial*)
PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] searched 29th May 2010 (limit: added in the last 90 days)
Craniocerebral Trauma [mh] OR Brain Edema [mh] OR Glasgow Coma Scale [mh] OR Glasgow Outcome Scale [mh] OR Uncon-
sciousness [mh] OR Cerebrovascular Trauma [mh] OR ((head OR cranial OR cerebral OR brain* OR intra-cranial OR inter-cranial)
AND (haematoma* OR hematoma* OR haemorrhag* OR hemorrhage* OR bleed* OR pressure)) OR (Glasgow AND scale) OR
(“diffuse axonal injury” OR “diffuse axonal injuries”) OR (“persistent vegetative state”) OR ((unconscious* OR coma* OR concuss*)
AND (injury* OR injuries OR trauma OR damage OR damaged OR wound* OR fracture* OR contusion* OR haematoma* OR
hematoma* OR haemorrhag* OR hemorrhag* OR bleed* OR pressure)) AND (Bradycor OR CP-0127 OR Anatibant OR LF16-
0687 OR XY2405 OR B2 OR Beta-2 OR Bradycor OR CP-0127 OR Anatibant OR LF16-0687 OR XY2405 AND (randomized
controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab]) OR (trial[ti])
OR (“Clinical Trials as Topic”[MeSH Major Topic])) NOT ((“Animals”[Mesh]) NOT (“Humans”[Mesh] AND “Animals”[Mesh]))
Zetoc searched (20 May 2009)
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Beta 2 + head
Beta 2 + brain
B2 + head
B2 + brain
Zetoc (11 April 08)
(Brain [and] injur* [and] (B2 or Beta-2 or Bradykinin* or Anatibant or LF16-0687 or XY2405 or Bradycor or CP-0127))
or (Head [and] injur* [and] (B2 or Beta-2 or Bradykinin* or Anatibant or LF16-0687 or XY2405 or Bradycor or CP-0127))
LILACS (May 2010)
(head OR brain OR cranial OR cerebral OR brain$ OR intra-cranial OR inter-cranial [Palavras] AND (haematoma$ OR hematoma$
OR haemorrhag$ OR hemorrhage$ OR bleed$ OR pressure OR injury$ OR injuries OR trauma OR damage OR damaged OR
wound$ OR fracture$) [Palavras] AND (bradykinin* OR B2 OR Beta2 OR B-2 OR Beta-2 OR Anatibant OR LF16-0687 OR
XY2405 OR Bradycor OR CP-0127 OR icatibant OR cereport OR CP-0597 OR (adrenergic* and antagonist*)) [Palavras]
WH A T ’ S N E W
Last assessed as up-to-date: 20 May 2010.
Date Event Description
21 May 2010 New search has been performed The search has been updated to 19 May 2010. No new trials were identified; the
conclusions remain the same
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 1, 2008
Date Event Description
19 January 2010 New search has been performed The results of the BRAIN trial have been incorporated. The trial had been
an ongoing study in previous versions of the review. The conclusions remain
unchanged
The title has been changed to specify the type of beta-2 receptor antagonist
(bradykinin)
20 May 2008 Amended The assessment of methodological quality sections in the ’Methods’ and ’Re-
sults’ section have been revised in light of updated Cochrane guidance pre-
sented in Higgins 2008. Risk of bias tables have been completed.
11 April 2008 New search has been performed Searches have been updated; no new studies were identified.
26 March 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
KB devised the search strategy and ran the searches. KK and KB screened the search output, assessed papers for eligibility and extracted
data. KK entered the data into RevMan and performed the analyses. KK took the lead in writing the review with KB contributing as
required.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• London School of Hygiene & Tropical Medicine, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The assessment of methodological quality used in earlier versions of this review, and for the protocol, has been replaced with an
assessment of the risk of bias. This amendment is in response to a change in The Cochrane Collaboration’s methodological guidance.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Adrenergic beta-2 Receptor Antagonists; Acute Disease; Brain Edema [drug therapy]; Brain Injuries [∗drug therapy; mortality];
Intracranial Pressure; Peptides [therapeutic use]; Quinolines [therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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